The biology and management of waterhemp in Indiana

Waterhemp is a dioecious weed species indigenous to the Midwestern United states yet it has only recently become problematic in agronomic crop production in Indiana. Waterhemp is a small-seeded broadleaf which has increased in prevalence in conjunction with an increase in conservation tillage practices. Waterhemp germinates and emerges from the top 3 cm of soil and is known to exhibit extended periods of continual emergence, longer than most other summer annual weed species that are typically present in agronomic production settings. As a C4 species, waterhemp then grows rapidly and is capable of producing thousands of seeds, while effectively competing with corn and soybean crops. Corn and soybean yields can be reduced by 50–70% when competing with waterhemp for an entire growing season. There are also many herbicide-resistant biotypes of waterhemp, which create additional management challenges beyond the competitive nature of this weed. The objective of this research was to evaluate the emergence, growth and development, and the influence of tillage and herbicides on waterhemp biology and management in Indiana. The emergence characteristics of waterhemp were evaluated in a fallow field study where waterhemp emergence was monitored weekly throughout the growing season from three different tillage systems; no tillage, a single tillage event, and two tillage events 30 days apart. Waterhemp densities were low in 2014 and there were no differences in emergence from either tillage system. Higher waterhemp densities in 2015 produced more emergence from both the no-tillage and the two tillage treatments compared to the single tillage treatment. In both years, a flush of emergence was observed after the second tillage event in the two tillage treatment. Waterhemp emergence was first observed on April 24, 2014 and April 16, 2015 and 50% of the total emergence had occurred by May 22, 2014 and May 15, 2015. Waterhemp emergence can be decreased with a single tillage event in high-density waterhemp infestations. A second field study evaluated waterhemp emergence in a soybean environment. A factorial experiment evaluated the influence of no-tillage and conventional tillage combined with soil residual and foliar herbicides on waterhemp emergence. Soybean were planted on May 8, 2014 and May 14, 2015, and waterhemp emergence was then monitored biweekly throughout the growing season. Wherever soil residual herbicides were utilized, regardless on tillage, there was very little waterhemp emergence. In plots with no residual herbicides, emergence was 152% to 223% greater from the no-tillage treatment. There were no times throughout the season in which weekly emergence was higher in the conventionally tilled plots compared to the no-tillage plots. Waterhemp emerged for 10 and 12 weeks after planting in 2014 and 2015, respectively, with no difference in duration of emergence from either tillage treatment. Soil residual herbicides and conventional tillage were able to decrease waterhemp emergence in soybean. A third study investigated the growth and development of five waterhemp populations grown in a common garden. Populations from Indiana, Illinois, Missouri, Iowa and Nebraska were established in May, June, and July to simulate a discontinuous germination pattern and were measured weekly for plant height and flowering, and finally harvested for biomass and seed yield. Plant biomass accumulations from the May (1,120 g plant-1) and June (1,069 g plant-1) establishment dates was greater than the July (266 g plant-1) establishment date. There were no differences in the mean biomass accumulation among the five populations in either the May or June establishment but the July establishment ranged from 195 to 338 g plant-1 across the populations. Seed yields were higher in the May (926,629 seeds plant-1) and June (828,905 seeds plant-1) establishment dates than the July (276,258 seeds plant-1) establishment date. The Illinois population flowered the latest of all the populations but was also among the tallest in all three establishment dates. The July establishment flowered the quickest after establishment, accumulated the least biomass, and had the fewest, but the largest seeds. This experiment showed the effect of establishment timing on waterhemp growth and development and differences among populations when grown in a common environment

Pheochromocytomas

Pheochromocytomas are rare catecholamine-secreting neuroendocrine tumors derived from chromaffin tissue of the adrenal medulla. Such tumors arising from the sympathetic ganglia of the thorax, abdomen, or pelvis are termed “paragangliomas” or “extra-adrenal pheochromocytomas.” The classic symptoms of these tumors are due to excess circulating levels of norepinephrine, epinephrine, or dopamine. Although 21% may be asymptomatic, the most common symptoms associated with pheochromocytomas include sweating, palpitations, and headaches in association with intermittent hypertension. If left untreated, excess catecholamines may result in hypertensive crisis leading to cardiac complications, cerebrovascular stroke, or ultimately sudden death. These catecholamine-secreting tumors are most commonly sporadic, but about 30% of patients have this disease as part of a familial disorder such as multiple endocrine neoplasia type 2 (MEN2) or von Hippel-Lindau (VHL) syndrome. Although most are benign, accurate recognition of pheochromocytomas with malignant potential and distant metastases remains a major diagnostic challenge. Advances in the field of molecular genetics have led to novel diagnostic and therapeutic strategies in an attempt to address this dilemma. Surgical excision of pheochromocytomas and paragangliomas is the mainstay of treatment and offers the only potential for cure. This chapter focuses on recent developments in the diagnosis of pheochromocytomas, encompassing biochemical, radiologic, histologic, and molecular analyzes. In addition, novel therapeutic strategies and advances in individualized targeted therapies for malignant pheochromocytomas will be discussed

Women millennials’ perceptions of pension savings through the use of autoenrollment in the UK pension system

There has been concern about younger people, and women in particular, not saving enough for retirement and how to encourage further saving. Therefore, this study—partly funded by the Fawcett Society in association with Scottish Widows—explores female millennials’ attitudes and motivations toward pension saving and automatic enrollment through the use of 40 semistructured interviews and a focus group. The findings show that although the introduction of autoenrollment pensions is generally positively received, pensions knowledge is still limited, and this intensifies the risk of undersaving for retirement among millennial women, particularly given women’s diverse work histories

Characterization of serine proteinase expression in agaricus bisporus and coprinopsis cinerea by using green fluorescent protein and the A. bisporus SPR1 Promoter

The Agaricus bisporus serine proteinase 1 (SPR1) appears to be significant in both mycelial nutrition and senescence of the fruiting body. We report on the construction of an SPR promoter::green fluorescent protein (GFP) fusion cassette, pGreen_hph1_SPR_GFP, for the investigation of temporal and developmental expression of SPR1 in homobasidiomycetes and to determine how expression is linked to physiological and environmental stimuli. Monitoring of A. bisporus pGreen_hph1_SPR_GFP transformants on media rich in ammonia or containing different nitrogen sources demonstrated that SPR1 is produced in response to available nitrogen. In A. bisporus fruiting bodies, GFP activity was localized to the stipe of postharvest senescing sporophores. pGreen_hph1_SPR_GFP was also transformed into the model basidiomycete Coprinopsis cinerea. Endogenous C. cinerea proteinase activity was profiled during liquid culture and fruiting body development. Maximum activity was observed in the mature cap, while activity dropped during autolysis. Analysis of the C. cinerea genome revealed seven genes showing significant homology to the A. bisporus SPR1 and SPR2 genes. These genes contain the aspartic acid, histidine, and serine residues common to serine proteinases. Analysis of the promoter regions revealed at least one CreA and several AreA regulatory motifs in all sequences. Fruiting was induced in C. cinerea dikaryons, and fluorescence was determined in different developmental stages. GFP expression was observed throughout the life cycle, demonstrating that serine proteinase can be active in all stages of C. cinerea fruiting body development. Serine proteinase expression (GFP fluorescence) was most concentrated during development of young tissue, which may be indicative of high protein turnover during cell differentiatio

Pensions Planning in the UK: A gendered challenge

Gender differences in the accumulation of pension savings are well documented. Work in this field has concluded that while differing lifetime work profiles (and family history) explained much of the difference, other factors such as pension knowledge and confidence in decisionmaking, may also be significant. This research, funded by the Fawcett Society in association with Scottish Widows, explores some of these factors through the use of 30 semi-structured interviews and a focus group with women (aged 24-39) about their attitudes and motivations towards pension saving. It concentrates on discussions around pension knowledge, advice and decision-making, and identifies challenges in relation to women’s pension knowledge and the use of male ‘role models’ in making decisions. The paper then explores potential policy mechanisms to enhance women’s pension saving for retirement, including the manner in which information and advice is provided and strategies to improve confidence in pension decision-making

MicroRNAs as Novel Biomarkers for Breast Cancer

Breast cancer is a complex phenotypically diverse genetic disease, involving a variety of changes in gene expression and structure. Recent advances in molecular profiling technology have made great progress in unravelling the molecular taxonomy of breast cancer, which has shed new light on the aetiology of the disease and also heralded great potential for the development of novel biomarkers and therapeutic targets. Mi(cro)RNAs are a contemporary class of small noncoding endogenous RNA molecules, generating great excitement in the clinical and scientific communities. The recent discovery that miRNA expression is frequently dysregulated in cancer has uncovered an entirely new repertoire of molecular factors upstream of gene expression, which warrants extensive investigation to further elucidate their precise role in malignancy. We present a comprehensive and timely review of the role of miRNAs in cancer: addressing miRNA function, their putative role as oncogenes or tumor suppressors, with a particular emphasis on breast cancer throughout. We discuss the recent discovery of quantifiable circulating cancer-associated miRNAs, which heralds immense potential for their use as novel minimally invasive biomarkers for breast and other cancers. Finally, we comment on the potential role of miRNAs in breast cancer management, particularly in improving current prognostic tools and achieving the goal of individualized cancer treatment

B-type natriuretic peptide-guided treatment for heart failure

Background Heart failure is a condition in which the heart does not pump enough blood to meet all the needs of the body. Symptoms of heart failure include breathlessness, fatigue and fluid retention. Outcomes for patients with heart failure are highly variable; however on average, these patients have a poor prognosis. Prognosis can be improved with early diagnosis and appropriate use of medical treatment, use of devices and transplantation. Patients with heart failure are high users of healthcare resources, not only due to drug and device treatments, but due to high costs of hospitalisation care. B‐type natriuretic peptide levels are already used as biomarkers for diagnosis and prognosis of heart failure, but could offer to clinicians a possible tool to guide drug treatment. This could optimise drug management in heart failure patients whilst allaying concerns over potential side effects due to drug intolerance. Objectives To assess whether treatment guided by serial BNP or NT‐proBNP (collectively referred to as NP) monitoring improves outcomes compared with treatment guided by clinical assessment alone. Search methods Searches were conducted up to 15 March 2016 in the Cochrane Central Register of Controlled Trials (CENTRAL) in the Cochrane Library; MEDLINE (OVID), Embase (OVID), the Database of Abstracts of Reviews of Effects (DARE) and the NHS Economic Evaluation Database in the Cochrane Library. Searches were also conducted in the Science Citation Index Expanded, the Conference Proceedings Citation Index on Web of Science (Thomson Reuters), World Health Organization International Clinical Trials Registry and ClinicalTrials.gov. We applied no date or language restrictions. Selection criteria We included randomised controlled trials of NP‐guided treatment of heart failure versus treatment guided by clinical assessment alone with no restriction on follow‐up. Adults treated for heart failure, in both in‐hospital and out‐of‐hospital settings, and trials reporting a clinical outcome were included. Data collection and analysis Two review authors independently selected studies for inclusion, extracted data and evaluated risk of bias. Risk ratios (RR) were calculated for dichotomous data, and pooled mean differences (MD) (with 95% confidence intervals (CI)) were calculated for continuous data. We contacted trial authors to obtain missing data. Using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach, we assessed the quality of the evidence and GRADE profiler (GRADEPRO) was used to import data from Review Manager to create a 'Summary of findings' table. Main results We included 18 randomised controlled trials with 3660 participants (range of mean age: 57 to 80 years) comparing NP‐guided treatment with clinical assessment alone. The evidence for all‐cause mortality using NP‐guided treatment showed uncertainty (RR 0.87, 95% CI 0.76 to 1.01; patients = 3169; studies = 15; low quality of the evidence), and for heart failure mortality (RR 0.84, 95% CI 0.54 to 1.30; patients = 853; studies = 6; low quality of evidence). The evidence suggested heart failure admission was reduced by NP‐guided treatment (38% versus 26%, RR 0.70, 95% CI 0.61 to 0.80; patients = 1928; studies = 10; low quality of evidence), but the evidence showed uncertainty for all‐cause admission (57% versus 53%, RR 0.93, 95% CI 0.84 to 1.03; patients = 1142; studies = 6; low quality of evidence). Six studies reported on adverse events, however the results could not be pooled (patients = 1144; low quality of evidence). Only four studies provided cost of treatment results, three of these studies reported a lower cost for NP‐guided treatment, whilst one reported a higher cost (results were not pooled; patients = 931, low quality of evidence). The evidence showed uncertainty for quality of life data (MD ‐0.03, 95% CI ‐1.18 to 1.13; patients = 1812; studies = 8; very low quality of evidence). We completed a 'Risk of bias' assessment for all studies. The impact of risk of bias from lack of blinding of outcome assessment and high attrition levels was examined by restricting analyses to only low 'Risk of bias' studies. Authors' conclusions In patients with heart failure low‐quality evidence showed a reduction in heart failure admission with NP‐guided treatment while low‐quality evidence showed uncertainty in the effect of NP‐guided treatment for all‐cause mortality, heart failure mortality, and all‐cause admission. Uncertainty in the effect was further shown by very low‐quality evidence for patient's quality of life. The evidence for adverse events and cost of treatment was low quality and we were unable to pool results.</p